Atea Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Other than as disclosed below, during the three months ended June 30, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminateda “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.
On June 17, 2024, Maria Arantxa Horga, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K. This arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to 67,198 shares of the Company’s common stock. The exact number of shares of common stock that will be sold is not determinable and will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 41,534 restricted stock units previously granted. The 10b5-1 plan expires on June 15, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.